Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Liminatus Pharma, Inc. (LIMN)

Liminatus Pharma Regains Nasdaq Bid Price Compliance After 1-for-50 Reverse Split

Positive Impact 3 of 5 legal/regulatory Written later

Nasdaq has determined that Liminatus Pharma regained compliance with its minimum bid price rule and closed the matter, according to an 8-K filed September 29, 2026. The company had transferred to The Nasdaq Capital Market effective August 4, 2026, after a hearing before the Nasdaq Hearings Panel, and completed a 1-for-50 reverse stock split on August 20, 2026. Its closing bid price was above $1.00 for 13 consecutive trading days, from August 21 to September 9, 2026.

Key points

  • Nasdaq notice dated September 24, 2026 said the company regained compliance with the Bid Price Rule and the matter is closed.
  • Closing bid price was above $1.00 for 13 consecutive trading days, August 21 to September 9, 2026.
  • The company effected a 1-for-50 reverse stock split at the close of trading on August 20, 2026.
  • Company issued a press release on September 29, 2026 (Exhibit 99.1) announcing the regained compliance.

The filing

CompanyLiminatus Pharma, Inc. (LIMN)
Form8-K, current report
Filed with the SECSep 29, 2026, 9:15 AM ET
Accession number0001104659-26-111665

Items reported: 3.01 Delisting / Listing Rule Notice7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.